A1,
A2,
B,
C1,
C2,
D,
E,
F,
G-H,
I-K,
L,
M,
N,
O,
P1,
P2,
Q-R,
S,
T,
U-V,
W-Z
Neostigmine Indications, Dosage, Storage, Stability - Neostigmine Methylsulfate (injection)
Neostigmine Indications, Dosage, Storage, Stability - Neostigmine Methylsulfate (injection)
INDICATIONS
Neostigmine Methylsulfate Injection, USP is indicated for:
- The symptomatic control of myasthenia gravis when oral therapy is
impractical.
- The prevention and treatment of postoperative distention and urinary
retention after mechanical obstruction has been excluded.
- Reversal of effects of nondepolarizing neuromuscular blocking agents
(e.g., tubocuranne, metocurine, gallamine or pancuronium) after surgery.
DOSAGE AND ADMINISTRATION
Symptomatic Control of Myasthenia Gravis
One mL of the 1:2000 solution (0.5 mg) IM or SC. Subsequent doses should
be based on the individual patient’s response.
Prevention of Postoperative Distention and Urinary Retention
One mLof the 1:4000 solution (0.25 mg) IM or SCas soon as possible after
operation; repeat every four to six hours for two or three days.
Treatment of Postoperative Distention
One mL of the 1:2000 solution (0.5 mg) IM or SC, as required.
Treatment of Urinary Retention
One mL of the 1:2000 solution (0.5 mg) IM or SC. If urination does not
occur within an hour, the patient should be catheterized. After the patient
has voided, or the bladder has been emptied, continue the 0.5 mg injections
every three hours for at least five injections.
Reversal of Effects of Nondepolarizing Neuromuscular Blocking Agents
When neostigmine methylsulfate is administered IV, it is recommended
that atropine sulfate (0.6 to 1.2 mg) also be given IV using separate
syringes. Some authorities have recommended that the atropine be injected
several minutes before the neostigmine methylsulfate rather than concomitantly.
The usual dose is 0.5 to 2 mg neostigmine methylsulfate given by
IV injection, repeated as required. Only in exceptional cases should the
total dose of neostigmine methylsulfate exceed 5 mg. It is recommended
that the patient be well ventilated and a patent airway maintained until
complete recovery of normal respiration is assured. The optimum time for
administration of the drug is during hyperventilation when the carbon
dioxide level of the blood is low. It should never be administered in
the presence of high concentrations of halothane or cyclopropane. In cardiac
cases and severely ill patients, it is advisable to titrate the exact
dose of neostigmine methylsulfate required, using a peripheral nerve stimulator
device. In the presence of bradycardia, the pulse rate should be increased
to about 80/min with atropine before administering neostigmine methylsulfate.
Parenteral drug products should be inspected visually for particulate
matter and discoloration prior to administration, whenever solution and
container permit.
HOW SUPPLIED
|
Product No.
|
NDC No.
|
|
|
38210
|
0469-3820-30
|
Neostigmine Methylsulfate Injection, USP (1 :2000)
0.5 mg/mL in a 10 mL amber flip-top multiple dose vial, in packages
of 10. |
|
38310
|
0469-3830-30
|
Neostigmine Methylsulfate Injection, USP (1: 1000) 1
mg/mL inalOmLamber flip-top multiple dose vial, in packages of 10. |
Store at controlled room temperature 15°-30°C (59°-86°F).
PROTECT FROM LIGHT.
Retain vial in carton until time of use.
CAUTION: Federal wlaw prohibits dispensing without prescription.
top
